Katia Khoury

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 12

Top Topics

Cardiovascular Risk Factors

Metastatic Colorectal Cancer

Top Venues

Nature communications

Nature medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda, Marie Davidian, Butch Tsiatis, A Jo Chien, Anne M Wallace, Mili Arora, Mariya Rozenblit, Dawn L Hershman, Alexandra S Zimmer, Amy S Clark, Heather Beckwith, Anthony D Elias, Erica Stringer-Reasor, Judy C Boughey, Chaitali Nangia, Christos Vaklavas, Coral Omene, Kathy S Albain, Kevin M Kalinsky, Claudine Isaacs, Jennifer Tseng, Evanthia T Roussos Torres, Brittani Thomas, Alexandra Thomas, Amy Sanford, Ronald Balassanian, Cheryl Ewing, Kay Yeung, Candice A M Sauder, Tara Sanft, Lajos Pusztai, Meghna S Trivedi, Ashton Outhaythip, Wen Li, Natsuko Onishi, Adam L Asare, Philip Beineke, Peter Norwood, Lamorna Brown Swigart, Gillian L Hirst, Jeffrey B Matthews, Brian Moore, W Fraser Symmans, Elissa Price, Carolyn Beedle, Jane Perlmutter, Paula R Pohlmann, Rebecca A Shatsky, Angela M DeMichele, Douglas Yee, Laura van 't Veer, Nola M Hylton, Laura J Esserman
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature medicine (2024)
Geoffrey Bostany, Yanjun Chen, Liton Francisco, Chen Dai, Qingrui Meng, Jessica Sparks, Min Sessions, Lisle M Nabell, Erica M Stringer-Reasor, Katia Khoury, Carrie Lenneman, Kimberly Keene, Saro H Armenian, Wendy Landier, Smita Bhatia
Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)